<DOC>
	<DOC>NCT01054092</DOC>
	<brief_summary>The primary objective of this study is to evaluate the long-term safety of ASP1941 in patients with type 2 diabetes mellitus. The second objectives are to compare the efficacy and pharmacokinetics of ASP1941 administered before or after food intake.</brief_summary>
	<brief_title>A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients</brief_title>
	<detailed_description>Subject will be randomized into either ASP1941 before meal or ASP1941 after meal groups. Subjects will undergo a screening period before entering the long-term treatment. Dosage may be increased during the treatment period if subjects fulfill increasing criteria and the investigators adjudicate that no impact for subjects safety.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Type 2 diabetic patients for at least 12 weeks HbA1c value between 6.5 and 9.5% Body Mass Index ( BMI )20.0 45.0kg/m2 Type 1 diabetes mellitus patients Serum creatinine &gt; upper limit of normal Proteinuria (albumin/creatinine ratio &gt; 300mg/g) Dysuria and/or urinary tract infection, genital infection Significant renal, hepatic or cardiovascular diseases Severe gastrointestinal diseases Proliferative diabetic retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Blood glucose</keyword>
	<keyword>Food effect</keyword>
</DOC>